- Home
- SORA vs PRPO Comparison
SORA vs PRPO Comparison
Compare SORA & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SORA | PRPO |
|---|---|---|
| Founded | 2001 | N/A |
| Country | Hong Kong | United States |
| Employees | 7 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.0M | 40.1M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | SORA | PRPO |
|---|---|---|
| Price | $1.90 | $24.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.7K | ★ 23.9K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.15 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,049,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $1.57 | $13.02 |
| 52 Week High | $7.51 | $33.63 |
Technical Indicators
Market Signals| Indicator | SORA | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 43.30 | 50.74 |
| Support Level | $1.84 | $22.32 |
| Resistance Level | $2.14 | $25.70 |
| Average True Range (ATR) | 0.30 | 1.97 |
| MACD | -0.01 | 0.35 |
| Stochastic Oscillator | 32.94 | 50.88 |
Price Performance
Historical ComparisonAbout SORA Top Win International Limited Ordinary Shares
AsiaStrategy is a wholesaler engaged in trading, distribution, and retail of luxury watches of international brands. The Group sources its luxury watches from Europe, Singapore, Japan, and Hong Kong, then sells the goods to retail sellers and other distributors in the watch industry.
About PRPO Precipio Inc.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.